scholarly journals Correction to: A double-blind placebo controlled study of acotiamide hydrochloride for efficacy on gastrointestinal motility of patients with functional dyspepsia

2021 ◽  
Vol 56 (2) ◽  
pp. 191-191
Author(s):  
Kumiko Nakamura ◽  
Toshihiko Tomita ◽  
Tadayuki Oshima ◽  
Haruki Asano ◽  
Takahisa Yamasaki ◽  
...  
2016 ◽  
Vol 52 (5) ◽  
pp. 602-610 ◽  
Author(s):  
Kumiko Nakamura ◽  
Toshihiko Tomita ◽  
Tadayuki Oshima ◽  
Haruki Asano ◽  
Takahisa Yamasaki ◽  
...  

2016 ◽  
Vol 150 (4) ◽  
pp. S159 ◽  
Author(s):  
Kumiko Nakamura ◽  
Toshihiko Tomita ◽  
Tadayuki Oshima ◽  
Tomohiro Ogawa ◽  
Ken Hara ◽  
...  

2018 ◽  
Vol 21 (11) ◽  
pp. 1120-1128 ◽  
Author(s):  
Muhammed Majeed ◽  
Shaheen Majeed ◽  
Kalyanam Nagabhushanam ◽  
Sivakumar Arumugam ◽  
Anurag Pande ◽  
...  

Gut and Liver ◽  
2011 ◽  
Vol 5 (4) ◽  
pp. 468-471 ◽  
Author(s):  
Su Jin Hong ◽  
In Kyung Sung ◽  
Jae Gyu Kim ◽  
Sang Woo Lee ◽  
Suck Chei Choi ◽  
...  

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Kadur Ramamurthy Raveendra ◽  
Jayachandra ◽  
Venkatappa Srinivasa ◽  
Kadur Raveendra Sushma ◽  
Joseph Joshua Allan ◽  
...  

A randomized, double-blind, placebo-controlled study was conducted to evaluate the efficacy of GutGard, an extract ofGlycyrrhiza glabra, in patients with functional dyspepsia. The primary outcome variables of the study were the change in the severity symptoms and the global assessment of efficacy. The quality of life was evaluated as a secondary outcome measure. The patients received either placebo or GutGard (75 mg twice daily) for 30 days. Efficacy was evaluated in terms of change in the severity of symptoms (as measured by 7-point Likert scale), the global assessment of efficacy, and the assessment of quality of life using the short-form Nepean Dyspepsia Index. In comparison with placebo, GutGard showed a significant decrease (P≤.05) in total symptom scores on day 15 and day 30, respectively. Similarly, GutGard showed marked improvement in the global assessment of efficacy in comparison to the placebo. The GutGard group also showed a significant decrease (P≤.05) in the Nepean dyspepsia index on day 15 and 30, respectively, when compared to placebo. GutGard was generally found to be safe and well-tolerated by all patients. GutGard has shown significant efficacy in the management of functional dyspepsia.


Sign in / Sign up

Export Citation Format

Share Document